Member Info for daveycaferacer

"— Thursday, April 8, 2021: Hutchison China MediTech Limited
(“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the
issuance of US$100 million of shares at a price equivalent to US$30.5 per American Depositary Share (“ADS”)
via a private placement to funds affiliated with Baring Private Equity Asia (“BPEA”)."

$100m becomes $65m and if I were Barings I would be seriously concerned about my investment

Analyst:-
" I'm just thinking about the proposed Shanghai listing given the listings already in the U.K., U.S. and Hong Kong. Is supporting four global listings a realistic expectation on your side over the future?"

Christian:-
"But I think three listings is a lot. Obviously, we've mentioned during this call that we are evaluating other opportunities as well. I think it's not realistic to go higher than three listings"

Code that if they list in Shanghai a listing will have to go, and surely, logically, that will be the London one.

5 years of stunning growth, and 5 years of gains wiped away. GA, CPF, Baring Asia, et al must surely be questioning their investment. How can a company with such progress simply have so much shareholder value erased by the market? It makes little sense. Los making yes, but those losses were expected.

https://www.trinitydelta.org/research-notes/a-genuinely-global-rd-driven-biopharma-business/

". We currently value HUTCHMED at US$8.84bn (US$52.12 per ADS), £6.8bn and HK$69.0bn (802p or HK$81.30 per share).

Theory is starkly different from reality when it comes to the valuation....unfortunately.

Larger losses shouldnt be a surprise, they were fully predicted and forecast by the company and Analysts

we won

Arbitral award in favor of Hutchison Sinopharm49 in connection with the termination of its distribution rights for SEROQUEL® in mainland China by Luye Pharma Hong Kong Ltd. In 2021, the Hong Kong International Arbitration Centre made a final award in favor of Hutchison Sinopharm against Luye Pharma Hong Kong Ltd. in the amount of RMB253.2 million ($39.6 million), plus costs and interest. Payment of the award is expected in 2022.

then again, Beigene is down 8%

Brilliant set of results, way ahead of expectations and a further 7% drop in the share price

Christian is retiring and returning to Europe after many years at Hutchmed and P&G in Asia - he has done a fantastic job building this Company from literally nothing into the global Biopharma it has now become. I am glad that he will still have some involvement in the Company and it has been a pleasure to meet him on many occasions.

surprised Macau has its own regulatory regime and a tiny market but progress nonetheless

Still here, still frustrated but still invested ;o-)

Hoping for EMA and FDA Surufatinib approval in the next few weeks and stellar results this week!

Here is what Trinity Delta said in July 2021...

"US$52.12/ADS or 802p/HK$81.30/share valuation Following the Hong Kong IPO and global offering, and recent China approvals of surufatinib (pNET) and savolitinib (NSCLC MET ex14m), our updated HUTCHMED valuation is US$8.84bn (US$52.12 per ADS), £6.8bn (802p per share), or HK$69.0bn (HK$81.30 per share)."

What happened? Geo-political nonsense alone?

thanks tacly, that should help to drive Savo sales

How can one possibly weigh up the geo-political risks that seem to change on a whim? It is difficult enough to select a Company to invest directly in based on the old fashioned investment case alone, but this geo-political nonsense is really getting in the way of progress.

more luaghter here:-

"Headquartered Offices: London, UK and
New York , NYHeadquartered Offices: London, UK and
New York , NY"

Call me old fashioned but a Corporation has one Headquarter, not multiple.

struggling to contain my laughter at this filing today

"We may offer, issue and sell from time to time up to $250,000,000, or its equivalent in any other currency, currency units, or composite currency or currencies, of our common shares, "

I've lost track of the shenanigans this company has played in the past two years. They need to focus on clinical development and either the disposal of Accustem or getting it to market instead of all the ludicrous corporate game playing they have engaged in

hi Niqash - you should have received your zero value Accustem shares, an asset that appears to have been taken from Tiziana shareholders without compensation. I don't know how the court could agree to a capital reduction without any form of commitment by the company on the timescales for a listing so people's assets have a value other than zero.

looking for EMA and FDA approval of Surufatinib by April, and really hoping for some great sales data in March on Surufatinib and Fruq as well as an important update on how the somewhat niche Savo sales are progressing.

What happens when a stock falls below $1 on the Nasdaq?
After the initial listing, if a stock's average closing price over any 30 consecutive trading days falls below $1, the stock is subject to delisting from the NYSE. This average closing price equals the sum of 30 consecutive closing prices, divided by 30. A closing price is the last trading price of a trading day.